Dermatology

Phase 3 ADORING data show tapinarof improves skin, itch, and sleep in children with atopic dermatitis, with similar efficacy and safety in those with comorbidities.

Phase 3 ADORING data show tapinarof cream delivers early, consistent skin, itch, and sleep improvements in children with atopic dermatitis, with low adverse event rates.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Despite advances, Arielle Kauvar, MD, calls for more research on laser and energy-based devices for patients with skin of color.

Colorblind energy devices and long-wavelength lasers are safest for darker skin, says Ariella Kauvar, MD, with a thorough patient history and physical exam key to preventing complications.

Arielle Kauvar, MD, says pre- and post-treatment care helps prevent hyperpigmentation and complications from laser procedures for all skin types, including skin of color.

Experts discussed safe and effective management strategies for patients with hidradenitis suppurativa at the 2025 Skin of Color Update.

Eliot F. Battle, MD, discusses how to effectively and successfully treat skin of color.

Jenifer Soung, MD, fo Southern California Dermatology, discussed how glucagon-like peptide-1 receptor agonists aid in treating patients with psoriatic disease.

Eliot F. Battle, MD, discusses the art of using lasers and energy-based technology to treat patients with skin of color.

Experts at the Skin of Color Update highlighted the potential benefits of GLP-1 RAs in managing obesity, as well as psoriasis and hidradenitis suppurativa symptom management.

Some comorbidities associated with psoriatic disease can be treated with GLP-1 RAs and multidisciplinary care.

Eliot F. Battle, MD, a dermatologist, reflects on how he chooses the right treatments for patients with skin of color.

Tiffany Mayo, MD, speaks on emerging therapies for treating hidradenitis suppurativa at the 2025 Skin of Color Update.

Tiffany Mayo, MD, discusses the emerging therapy landscape for treating patients with hidradenitis suppurativa.

FDA approvals since the last Skin of Color Update expand topical and biologic options for various dermatological conditions, benefiting patients with skin of color.

Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.

The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis.

Ruxolitinib cream 15 mg/g provided rapid, meaningful repigmentation and improved quality of life for adults with nonsegmental vitiligo.

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.